23 completed. 23 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 23 | Completed 23 |
Follow Reference: new trials by email Literature Review of Reference trials Research Report on Reference
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bioequivalence Study of ADC118 Tablets in Healthy Chinese Volunteers Under Fasting Conditions ACC118-Test, Reference - Human Immunodeficiency Virus (HIV) Infection | Phase 1 | Completed | Jiangsu Aidea Pharmaceutical Group Co., Ltd. | 48 | 2026-04-10 | 2026-08-10 |
| Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy Volunteers CKD-383 0.25/12.5/1000mg, CKD-501, D745, D150 - Type 2 Diabetes | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 30 | 2025-10-30 | 2025-12-26 |
| Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy Volunteers CKD-383 0.5/10/1000mg, CKD-501, D744, D150 - Type 2 Diabetes | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 30 | 2025-10-28 | 2025-12-26 |
| Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/25/1000mg in Healthy Volunteers CKD-383 0.5/25/1000mg, CKD-501, D745, D150 - Type 2 Diabetes | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 31 | 2025-10-24 | 2025-12-26 |
| Bioequivalence Study of Vortioxetine in 20 mg Coated Tablets in Healthy Subjects Under Fasting Conditions Reference, Test - Bioequivalance | Phase 1 | Completed | ADIUM | 20 | 2025-03-18 | 2026-06-03 |
| A Study to Compare Pharmacokinetics, Pharmacodynamics and Safety of UI059 and UIC202201 in Healthy Subjects UI059, UIC202201 - GERD | Phase 1 | Completed | Korea United Pharm. Inc. | 8 | 2023-10-08 | 2023-11-21 |
| A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices LY3437943, Test, Reference - Healthy | Phase 1 | Completed | Eli Lilly and Company | 57 | 2023-08-29 | 2024-03-29 |
| Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-386 in Healthy Volunteers Under Fasting Conditions CKD-386(4) F1, CKD-386(4) F2, D013, D326, D337 - Hypertension and Dyslipidemia | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 31 | 2022-09-23 | 2023-01-12 |
| Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fed Conditions CKD-387, D484 - Endocrine, Nutritional and Metabolic Diseases | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 31 | 2022-09-19 | 2024-05-03 |
| Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fasting Conditions CKD-387, D484 - Endocrine, Nutritional and Metabolic Diseases | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 37 | 2022-09-16 | 2024-05-03 |
| Clinical Trial to Evaluate the Pharmacokinetic Characteristics of DW5221 and DW5221-R DW5221, DW5221-R - Apetite Stimulants | Phase 1 | Completed | Daewon Pharmaceutical Co., Ltd. | 54 | 2022-07-01 | 2023-11-28 |
| Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388(2) in Healthy Subjects D418 Tab., CKD-388 Tab. - Chronic Hepatitis b | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 65 | 2022-01-14 | 2022-09-28 |
| Clinical Study to Compare the Pharmacokinetics and Safety of D113 With CKD-349 in Healthy Volunteers CKD-349 F1 Tab., CKD-349 F2 Tab., D113 Tab. - Chronic Renal Failure | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 25 | 2021-07-19 | 2024-01-24 |
| Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of DA-2803 in Healthy Subjects Vemlidy Tab, DA-2803 Tab - Hepatitis B | Phase 1 | Completed | Dong-A ST Co., Ltd. | 96 | 2021-07-12 | 2022-07-14 |
| A Study to Compare PK, PD and Safety of UI058 and UIC202004 in Healthy Subjects administration of UI058, administration of UIC202004 - GERD | Phase 1 | Completed | Korea United Pharm. Inc. | 41 | 2021-02-03 | 2024-07-03 |
| A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809 DW1809, DW1809-1 - Osteoarthritis, Rheumatoid Arthritis | Phase 1 | Completed | Daewon Pharmaceutical Co., Ltd. | 38 | 2020-08-15 | 2022-01-31 |
| A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809-T2 DW1809-T2, DW1809-1 - Osteoarthritis, Rheumatoid Arthritis | Phase 1 | Completed | Daewon Pharmaceutical Co., Ltd. | 37 | 2020-08-13 | 2022-01-31 |
| Bioequivalence Study of Favir 200 mg Film Tablet Kocak Under Fasting Conditions FAVIR 200 MG FT, AVIGAN 200 mg FT - Bioequivalence | Phase 1 | Completed | Kocak Farma | 30 | 2020-06-05 | 2020-11-30 |
| Bioequivalence Bewteen DopaSnap® (Cabidopa/Levopdoap 25/100 mg Tablet) and Carbidopa/Levodopa 25/100 mg Tablet (Actavis) DopaSnap®, RDL of CD-LD - Other | Phase 1 | Completed | Riverside Pharmacueticals Corporation | 57 | 2019-07-15 | 2020-01-22 |
| A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade (BREATH-PK250-CC) Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals, SERETIDE DISKUS® 250/50 inhalation powder/GSK, Activated Charcoal suspension - Bioequivalence | Phase 1 | Completed | Respirent Pharmaceuticals Co Ltd. | 36 | 2019-03-12 | 2019-06-05 |
Showing 20 of 23. Sign in to see all of them.
Diabetes Mellitus, Type 2 (3) · Arthritis, Rheumatoid (2) · Back Pain (2) · Gastroesophageal Reflux (2) · Metabolic Diseases (2) · Osteoarthritis (2) · Acquired Immunodeficiency Syndrome (1) · COVID-19 (1) · Dyslipidemias (1) · Hepatitis B (1) · Hepatitis B, Chronic (1) · Hypertension (1) · Kidney Failure, Chronic (1)
Chong Kun Dang Pharmaceutical (8) · Daewon Pharmaceutical Co., Ltd. (3) · Korea United Pharm. Inc. (2) · ADIUM (1) · Dong-A ST Co., Ltd. (1) · Eli Lilly and Company (1) · Jiangsu Aidea Pharmaceutical Group Co., Ltd. (1) · Kocak Farma (1) · Mepha Ltd. (1) · Reckitt Benckiser Healthcare (UK) Limited (1) · Respirent Pharmaceuticals Co Ltd. (1) · Riverside Pharmacueticals Corporation (1) · Sun Pharma Advanced Research Company Limited (1)
South Korea (14) · Canada (2) · China (1) · Germany (1) · Greece (1) · Mexico (1) · Turkey (Türkiye) (1) · United States (1)
Frank Donath, MD (1) · Jaewoo Kim (1) · Jaewoo Kim, M.D. (1) · Jang Hee Hong (1) · Min Kyu Park, Dr (1) · Minkyu Park, Dr (1) · Muradiye Nacak, MD,PhD (1) · Robert Adams, MBBS (1) · Stephane Lamouche, PhD (1) · Taner Ezgi, MD (1)